<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985985</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-Nicotine Mint Lozenge-002</org_study_id>
    <nct_id>NCT00985985</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate Efficacy and Safety of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blind, placebo-controlled, 4-arm clinical study to
      evaluate efficacy and safety of nicotine lozenge (2mg and 4mg) in smoking cessation in adult
      cigarette smokers who are motivated to quit smoking. Successful quitters or participants who
      smoke occasionally will be followed up after week 24 till 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Successful Smoking Cessation at Week 6</measure>
    <time_frame>From baseline to Week 6</time_frame>
    <description>Rate of Successful Smoking Cessation at Week 6 was measured by Carbon Monoxide (CO) breath levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Continuous Successful Smoking Cessation at Week 12 and Week 24</measure>
    <time_frame>From baseline to Week 12 and Week 24</time_frame>
    <description>Continuous abstinence was verified by measurement of CO breath levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Long-term Successful Smoking Cessation at Week 24</measure>
    <time_frame>From Week 6 to Week 24</time_frame>
    <description>Rate of long-term successful smoking cessation at Week 24 was defined as the proportion of participants who achieved the primary end-point with no more than six cumulative days of smoking from Week 6 to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Seven Day Point Prevalence Abstinence</measure>
    <time_frame>Weekly assessment at Week 1, 2, 4, 6, 12 and Week 24</time_frame>
    <description>Seven day point prevalence abstinence was defined as complete abstinence from smoking for the 7 days up to and including the evaluation day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Score of Relief of Craving/ Total Withdrawal Symptoms</measure>
    <time_frame>Weekly assessment at Week 1, 2, 3, 4, 5 and Week 6</time_frame>
    <description>The evaluation of withdrawal and craving symptoms was carried out every day with the Minnesota Nicotine Withdrawal scale (MNWS). The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated on a 5 grade scale with scores ranging from 0 (best score) to 4 (worst score) i.e. none (score=0), slight (score=1), mild (score=2), moderate (score=3), and severe (score=4). For each symptom at each week, the average score was calculated as the average of the daily scores during that week. The total score was calculated as the sum of the 9 symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Dose at Visit 4, 5, 6, 7 and 10</measure>
    <time_frame>Weeks 1-2, 3-4, 5-6, 7-12 and 13-24</time_frame>
    <description>Mean daily dose of lozenges was calculated as number of lozenges taken at each visit divided by days since the last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Body Weight at Week 6, Week 12 and Week 24/ Premature Termination.</measure>
    <time_frame>Baseline, Week 6, 12 and Week 24</time_frame>
    <description>Change in body weight was analyzed at Weeks 6, 12, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Cardiovascular AEs and Who Discontinued Due to AEs</measure>
    <time_frame>Weekly assessments from first treatment dose up to 15 days after last treatment dose</time_frame>
    <description>All AEs and SAEs were reviewed and reported by investigator. AEs were graded on a 3-point scale as Mild, Moderate and Severe.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">723</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>2mg nicotine lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg nicotine lozenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 mg placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg nicotine lozenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg nicotine lozenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mg placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>2 mg or 4 mg nicotine lozenge</description>
    <arm_group_label>2mg nicotine lozenge</arm_group_label>
    <arm_group_label>4 mg nicotine lozenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo lozenge</description>
    <arm_group_label>2 mg placebo</arm_group_label>
    <arm_group_label>4 mg placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be 18 years of age or older;

          -  Participant is motivated in smoking cessation using nicotine mint lozenge;

          -  Participant has the habit of smoking regularly every day for at least 1 year;

          -  Participant is able to read and provide written informed consent.

        Exclusion Criteria:

          -  Participant uses other forms of tobacco other than cigarettes such as pipes, cigars,
             snuff, or smokeless tobacco within 30 days of entry into the study;

          -  Participant uses other nicotine delivery system such as nicotine gum, nicotine patch,
             nicotine inhaler, or nicotine nasal spray etc. within 30 days of study entry;

          -  Participant smoke any other substance within 30 days of study entry (such as cannabis,
             cocaine, heroin, ice drug, herbal cigarettes etc);

          -  The participant has a past history of alcohol or drug abuse;

          -  Participants use other smoking cessation aids (including bupropion, varenicline,
             traditional Chinese medicines such as herbals, acupuncture, consultation etc), within
             30 days of study entry.;

          -  Participant is currently involved in another clinical trial or has used any
             investigational medication within 30 days of study entry; Any previous participation
             in this study;

          -  Participant is a member of the same household as another clinical subject. Subject is
             a relative of study site staff or member of the study staff;

          -  Participant is pregnant or breast-feeding, or has childbearing potential but refusing
             taking medical contraception measures (within first 24 weeks during study). (Note: All
             female subjects with childbearing potential must take urine pregnancy test before
             entry the study, only negative result subject is permitted to this study.);

          -  Participants who have heart and cerebral vascular disease not stable or controlled by
             medication or have an irregular heartbeat or have had a heart attack within the last 3
             months;

          -  Participants with poorly controlled high blood pressure by medications, systolic BP
             greater than or equal to 140mmHg, diastolic BP greater than or equal to 90mmHg after
             administration;

          -  Participants having hyperthyroidism or current application of insulin for diabetes;

          -  Participants having myocardial infarction or cerebral vascular accidents recently
             (within the past 3 months);

          -  Participants who are unable to fulfill study requirements in relation to conforming to
             the visit schedule;

          -  Participants who are allergy to Aspartame or Phenylpyruvic acid (an edulcorant is
             widely used in foods and drinks)ï¼Œor have diagnosed with Phenylketonuria;

          -  The other clinically significant pulmonary, gastrointestinal, liver, neurological,
             renal or haematological abnormalities.( unstable or worsening angina pectoris,
             Prinzmetal's angina, nerve or circulatory problems, rheumatoid arthritis, moderate and
             severe COPD);

          -  A medical history that, in the opinion of the investigator, might jeopardize the
             safety of the subject or the validity for the study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2009</study_first_posted>
  <results_first_submitted>July 25, 2013</results_first_submitted>
  <results_first_submitted_qc>June 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smoking cessation</keyword>
  <keyword>nicotine lozenge</keyword>
  <keyword>nicotine replacement therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at the clinical site.</recruitment_details>
      <pre_assignment_details>Of 781 screened participants, only 723 were randomized and remaining 58 were considered screening failures. Participants who smoked their first cigarette within 30 minutes after waking were considered as high dependence smokers while those who smoked their first cigarette after 30 minutes of waking were considered as low dependence smokers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Lozenge 2 Milligram (mg) (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes of waking received 2 mg of nicotine lozenge, orally. During week 1 to week 6,participants were recommended to take at least 9 lozenges per day, but not exceeding 15 lozenges. During week 7 to week 9, participants were recommended to use 12 to 6 lozenges per day, further taking 3 to 6 lozenges only by week 10 to 12. Afterwards, lozenge was taken when necessary to prevent relapse.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Lozenge (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes of waking received placebo lozenge containing 0 mg of nicotine, orally. During week 1 to week 6, participants were recommended to take atleast 9 lozenges per day but not exceeding 15 lozenges. During week 7 to week 9, participants were recommended to use 12 to 6 lozenges per day, further taking 3 to 6 lozenges only by week 10 to 12. Afterwards, lozenge was taken when necessary to prevent relapse</description>
        </group>
        <group group_id="P3">
          <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received 4 mg nicotine lozenge, orally. During week 1 to week 6, participants were recommended to take at least 9 lozenges per day but not exceeding 15 lozenges. During week 7 to week 9, participants were recommended to use 12 to 6 lozenge per day, further taking 3 to 6 lozenges only by week 10 to 12. Afterwards, lozenge was taken when necessary to prevent relapse.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Lozenge (High Dependence Smoke</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received placebo lozenge containing 0 mg of nicotine, orally. During week 1 to week 6, participants were recommended to take at least 9 lozenges per day but not exceeding 15 lozenges. During week 7 to week 9, participants were recommended to use 12 to 6 lozenge per day, further taking 3 to 6 lozenges only by week 10 to 12. Afterwards, lozenge was taken when necessary to prevent relapse.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="242"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="242"/>
                <participants group_id="P3" count="119"/>
                <participants group_id="P4" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS) Population</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="242"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="119">One participant withdrew consent and was not included as the FAS population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="218"/>
                <participants group_id="P3" count="109"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes of waking received 2 mg of nicotine lozenge, orally.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Lozenge (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes of waking received placebo lozenge containing 0 mg of nicotine, orally.</description>
        </group>
        <group group_id="B3">
          <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received 4 mg nicotine lozenge, orally.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Lozenge (High Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received placebo lozenge containing 0 mg of nicotine, orally.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="241"/>
            <count group_id="B2" value="242"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="119"/>
            <count group_id="B5" value="722"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline parameters were evaluated for FAS population.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="11.78"/>
                    <measurement group_id="B2" value="39.9" spread="11.76"/>
                    <measurement group_id="B3" value="42.3" spread="10.38"/>
                    <measurement group_id="B4" value="42.0" spread="10.57"/>
                    <measurement group_id="B5" value="40.1" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline parameter were evaluated for FAS population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <description>Baseline Parameters were evaluated for FAS population.</description>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="11.06"/>
                    <measurement group_id="B2" value="72.3" spread="11.42"/>
                    <measurement group_id="B3" value="75.9" spread="11.64"/>
                    <measurement group_id="B4" value="74.3" spread="12.15"/>
                    <measurement group_id="B5" value="73.1" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Successful Smoking Cessation at Week 6</title>
        <description>Rate of Successful Smoking Cessation at Week 6 was measured by Carbon Monoxide (CO) breath levels.</description>
        <time_frame>From baseline to Week 6</time_frame>
        <population>Analysis was considered per Full Analysis Set (FAS) population. FAS population consisted of all randomized participants who had study medication for at least once with assessment data post-dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Successful Smoking Cessation at Week 6</title>
          <description>Rate of Successful Smoking Cessation at Week 6 was measured by Carbon Monoxide (CO) breath levels.</description>
          <population>Analysis was considered per Full Analysis Set (FAS) population. FAS population consisted of all randomized participants who had study medication for at least once with assessment data post-dosing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.48"/>
                    <measurement group_id="O2" value="21.49"/>
                    <measurement group_id="O3" value="30.83"/>
                    <measurement group_id="O4" value="20.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered no treatment difference in the smoking cessation success rate for the active treatment versus its matching placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3851</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
            <estimate_desc>Odds Ratio based on logistic model (adjusted by center)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis considered no treatment difference in the smoking cessation success rate for the active treatment versus its matching placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0565</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>3.32</ci_upper_limit>
            <estimate_desc>Odds Ratio based on logistic model (adjusted by center).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Continuous Successful Smoking Cessation at Week 12 and Week 24</title>
        <description>Continuous abstinence was verified by measurement of CO breath levels.</description>
        <time_frame>From baseline to Week 12 and Week 24</time_frame>
        <population>Analysis was done per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Continuous Successful Smoking Cessation at Week 12 and Week 24</title>
          <description>Continuous abstinence was verified by measurement of CO breath levels.</description>
          <population>Analysis was done per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Smoking Cessation Rate at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.84"/>
                    <measurement group_id="O2" value="16.94"/>
                    <measurement group_id="O3" value="22.50"/>
                    <measurement group_id="O4" value="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Cessation Rate at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.86"/>
                    <measurement group_id="O2" value="13.22"/>
                    <measurement group_id="O3" value="19.17"/>
                    <measurement group_id="O4" value="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Long-term Successful Smoking Cessation at Week 24</title>
        <description>Rate of long-term successful smoking cessation at Week 24 was defined as the proportion of participants who achieved the primary end-point with no more than six cumulative days of smoking from Week 6 to Week 24.</description>
        <time_frame>From Week 6 to Week 24</time_frame>
        <population>Analysis was done per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Long-term Successful Smoking Cessation at Week 24</title>
          <description>Rate of long-term successful smoking cessation at Week 24 was defined as the proportion of participants who achieved the primary end-point with no more than six cumulative days of smoking from Week 6 to Week 24.</description>
          <population>Analysis was done per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.09"/>
                    <measurement group_id="O2" value="17.77"/>
                    <measurement group_id="O3" value="24.17"/>
                    <measurement group_id="O4" value="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Seven Day Point Prevalence Abstinence</title>
        <description>Seven day point prevalence abstinence was defined as complete abstinence from smoking for the 7 days up to and including the evaluation day.</description>
        <time_frame>Weekly assessment at Week 1, 2, 4, 6, 12 and Week 24</time_frame>
        <population>Analysis was carried out per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Seven Day Point Prevalence Abstinence</title>
          <description>Seven day point prevalence abstinence was defined as complete abstinence from smoking for the 7 days up to and including the evaluation day.</description>
          <population>Analysis was carried out per FAS population. FAS population consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.45"/>
                    <measurement group_id="O2" value="11.98"/>
                    <measurement group_id="O3" value="20.00"/>
                    <measurement group_id="O4" value="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.16"/>
                    <measurement group_id="O2" value="23.14"/>
                    <measurement group_id="O3" value="33.33"/>
                    <measurement group_id="O4" value="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.95"/>
                    <measurement group_id="O2" value="29.34"/>
                    <measurement group_id="O3" value="36.67"/>
                    <measurement group_id="O4" value="30.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.68"/>
                    <measurement group_id="O2" value="37.19"/>
                    <measurement group_id="O3" value="41.67"/>
                    <measurement group_id="O4" value="32.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.49"/>
                    <measurement group_id="O2" value="39.26"/>
                    <measurement group_id="O3" value="40.83"/>
                    <measurement group_id="O4" value="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.49"/>
                    <measurement group_id="O2" value="43.80"/>
                    <measurement group_id="O3" value="50.00"/>
                    <measurement group_id="O4" value="43.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Score of Relief of Craving/ Total Withdrawal Symptoms</title>
        <description>The evaluation of withdrawal and craving symptoms was carried out every day with the Minnesota Nicotine Withdrawal scale (MNWS). The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated on a 5 grade scale with scores ranging from 0 (best score) to 4 (worst score) i.e. none (score=0), slight (score=1), mild (score=2), moderate (score=3), and severe (score=4). For each symptom at each week, the average score was calculated as the average of the daily scores during that week. The total score was calculated as the sum of the 9 symptoms.</description>
        <time_frame>Weekly assessment at Week 1, 2, 3, 4, 5 and Week 6</time_frame>
        <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who have had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the number of participants analyzed (n) for this outcome measure. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score of Relief of Craving/ Total Withdrawal Symptoms</title>
          <description>The evaluation of withdrawal and craving symptoms was carried out every day with the Minnesota Nicotine Withdrawal scale (MNWS). The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated on a 5 grade scale with scores ranging from 0 (best score) to 4 (worst score) i.e. none (score=0), slight (score=1), mild (score=2), moderate (score=3), and severe (score=4). For each symptom at each week, the average score was calculated as the average of the daily scores during that week. The total score was calculated as the sum of the 9 symptoms.</description>
          <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who have had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the number of participants analyzed (n) for this outcome measure. Missing values were not imputed.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=236, 238, 119, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="7.18"/>
                    <measurement group_id="O2" value="7.77" spread="6.55"/>
                    <measurement group_id="O3" value="7.66" spread="6.08"/>
                    <measurement group_id="O4" value="8.67" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=230, 233, 112, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.59" spread="7.25"/>
                    <measurement group_id="O2" value="6.84" spread="6.05"/>
                    <measurement group_id="O3" value="6.70" spread="5.96"/>
                    <measurement group_id="O4" value="7.39" spread="6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=226, 232, 115, 110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="7.12"/>
                    <measurement group_id="O2" value="6.06" spread="5.83"/>
                    <measurement group_id="O3" value="6.17" spread="6.40"/>
                    <measurement group_id="O4" value="6.90" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=225, 226, 113, 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" spread="7.36"/>
                    <measurement group_id="O2" value="5.45" spread="5.59"/>
                    <measurement group_id="O3" value="5.66" spread="6.19"/>
                    <measurement group_id="O4" value="6.71" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=221, 229, 112, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="6.57"/>
                    <measurement group_id="O2" value="5.29" spread="5.72"/>
                    <measurement group_id="O3" value="5.60" spread="5.98"/>
                    <measurement group_id="O4" value="6.60" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (215, 223, 103, 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="6.53"/>
                    <measurement group_id="O2" value="5.45" spread="6.02"/>
                    <measurement group_id="O3" value="5.21" spread="5.58"/>
                    <measurement group_id="O4" value="6.49" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Dose at Visit 4, 5, 6, 7 and 10</title>
        <description>Mean daily dose of lozenges was calculated as number of lozenges taken at each visit divided by days since the last visit.</description>
        <time_frame>Weeks 1-2, 3-4, 5-6, 7-12 and 13-24</time_frame>
        <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the population analyzed (n) for this outcome measure at each time point. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Dose at Visit 4, 5, 6, 7 and 10</title>
          <description>Mean daily dose of lozenges was calculated as number of lozenges taken at each visit divided by days since the last visit.</description>
          <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the population analyzed (n) for this outcome measure at each time point. Missing values were not imputed.</population>
          <units>Number of lozenges</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1-2 (n=232, 237, 117, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.96" spread="3.32"/>
                    <measurement group_id="O2" value="8.59" spread="3.23"/>
                    <measurement group_id="O3" value="8.81" spread="3.57"/>
                    <measurement group_id="O4" value="8.52" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3-4 (n=224, 231, 114, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.66" spread="3.17"/>
                    <measurement group_id="O2" value="8.71" spread="3.40"/>
                    <measurement group_id="O3" value="8.93" spread="3.17"/>
                    <measurement group_id="O4" value="8.60" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5-6 (n=223, 228, 113, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" spread="3.39"/>
                    <measurement group_id="O2" value="8.07" spread="3.30"/>
                    <measurement group_id="O3" value="8.55" spread="3.32"/>
                    <measurement group_id="O4" value="8.09" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 7-12 (n=221, 224, 112, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="2.33"/>
                    <measurement group_id="O2" value="4.54" spread="2.40"/>
                    <measurement group_id="O3" value="5.02" spread="2.35"/>
                    <measurement group_id="O4" value="4.67" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weeks 13-24 (n=222, 222, 105, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="1.05"/>
                    <measurement group_id="O2" value="0.78" spread="1.04"/>
                    <measurement group_id="O3" value="0.95" spread="0.90"/>
                    <measurement group_id="O4" value="0.84" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Body Weight at Week 6, Week 12 and Week 24/ Premature Termination.</title>
        <description>Change in body weight was analyzed at Weeks 6, 12, and 24.</description>
        <time_frame>Baseline, Week 6, 12 and Week 24</time_frame>
        <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the population analyzed (n) for this outcome measure at each time point i.e. Week 6, Week 12 and Week 24. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge, orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received 4 mg nicotine lozenge orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking, received placebo lozenge containing 0 mg of nicotine orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Body Weight at Week 6, Week 12 and Week 24/ Premature Termination.</title>
          <description>Change in body weight was analyzed at Weeks 6, 12, and 24.</description>
          <population>Analysis was carried out per FAS population, which consisted of all randomized subjects who had study medication for at least once with assessment data post-dosing. Due to drop outs, there was difference in the population analyzed (n) for this outcome measure at each time point i.e. Week 6, Week 12 and Week 24. Missing values were not imputed.</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="120"/>
                <count group_id="O4" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=225, 230, 115, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.94"/>
                    <measurement group_id="O2" value="0.7" spread="2.21"/>
                    <measurement group_id="O3" value="1.2" spread="2.45"/>
                    <measurement group_id="O4" value="1.2" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=221, 225, 112, 107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.43"/>
                    <measurement group_id="O2" value="1.0" spread="2.40"/>
                    <measurement group_id="O3" value="1.9" spread="3.58"/>
                    <measurement group_id="O4" value="1.5" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=221, 224, 111, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.89"/>
                    <measurement group_id="O2" value="1.3" spread="2.81"/>
                    <measurement group_id="O3" value="2.2" spread="3.14"/>
                    <measurement group_id="O4" value="2.1" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Cardiovascular AEs and Who Discontinued Due to AEs</title>
        <description>All AEs and SAEs were reviewed and reported by investigator. AEs were graded on a 3-point scale as Mild, Moderate and Severe.</description>
        <time_frame>Weekly assessments from first treatment dose up to 15 days after last treatment dose</time_frame>
        <population>Safety Population of this study consists of all randomized participants who have had study medication for at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received 2 mg of nicotine lozenge, orally.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenge (Low Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette after 30 minutes of waking, received placebo lozenge containing 0 mg of nicotine, orally.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking received 4 mg nicotine lozenge, orally.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Lozenge (High Dependence Smokers)</title>
            <description>Participants, who smoked their first cigarette within 30 minutes after waking received placebo lozenge containing 0 mg of nicotine, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Cardiovascular AEs and Who Discontinued Due to AEs</title>
          <description>All AEs and SAEs were reviewed and reported by investigator. AEs were graded on a 3-point scale as Mild, Moderate and Severe.</description>
          <population>Safety Population of this study consists of all randomized participants who have had study medication for at least once.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events that occured in time-period from the first administration of product to up to 15 days after the last dosing were recorded</time_frame>
      <desc>Safety evaluation was done for saftey set population. There was one additional subject, randomized to 4mg Placebo, who withdrew consent, but was excluded from the SS population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Lozenge 2 mg (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes after waking received 2 mg of nicotine lozenge, orally.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Lozenge (Low Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette after 30 minutes after waking received placebo lozenge containing 0 mg of nicotine, orally.</description>
        </group>
        <group group_id="E3">
          <title>Nicotine Lozenge 4 mg (High Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received 4 mg of nicotine lozenge, orally.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Lozenge (High Dependence Smokers)</title>
          <description>Participants who smoked their first cigarette within 30 minutes after waking received placebo lozenge containing 0 mg of nicotine, orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="241"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="242"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

